Head-To-Head Analysis: Genetic Technologies (NASDAQ:GENE) versus Prime Medicine (NYSE:PRME)

Prime Medicine (NYSE:PRME) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Volatility and Risk

Prime Medicine has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Prime Medicine and Genetic Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	0	9	1	3.10
Genetic Technologies	0	0	0	0	0.00

Prime Medicine presently has a consensus price target of $13.13, indicating a potential upside of 406.76%. Given Prime Medicine’s stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than Genetic Technologies.

Insider and Institutional Ownership

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by company insiders. Comparatively, 6.5% of Genetic Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Prime Medicine and Genetic Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-107.87%	-74.97%
Genetic Technologies	N/A	N/A	N/A

Earnings & Valuation

This table compares Prime Medicine and Genetic Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	N/A	N/A	-$198.13 million	($2.05)	-1.26
Genetic Technologies	$7.66 million	0.44	-$7.88 million	N/A	N/A

Genetic Technologies has higher revenue and earnings than Prime Medicine.

Summary

Prime Medicine beats Genetic Technologies on 7 of the 11 factors compared between the two stocks.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.